Novartis Settles US Exforge Case For $245m
Originator Had Been Accused Of Unlawful Deal With Par To Maintain Monopoly
Novartis has agreed to pay out $245m to purchasers and retailers to resolve a lawsuit accusing the originator of an unlawful deal with Par that delayed US competition to the Exforge antihypertensive.
